<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312986</url>
  </required_header>
  <id_info>
    <org_study_id>201506131</org_study_id>
    <nct_id>NCT02312986</nct_id>
  </id_info>
  <brief_title>FMT for Multidrug Resistant Organism Reversal</brief_title>
  <official_title>Use of Fecal Microbiota Transplantation (FMT) to Reverse Multi-Drug Resistant Organism Carriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed protocol involves the use of the fecal microbiota transplantation (FMT) to&#xD;
      suppress or reverse colonization with multidrug resistant organisms (MDRO) in subjects with&#xD;
      recurrent MDRO infections due to organisms of likely enteric origin.&#xD;
&#xD;
      FMT will be performed on subjects with a history of at least three recurrent infections due&#xD;
      to MDRO; at least two recurrent, severe infections due to MDRO requiring hospitalization; or&#xD;
      at least two recurrent infections due to MDRO for which only antimicrobials with rate&#xD;
      limiting toxicities are available.&#xD;
&#xD;
      The objective of this protocol is to determine if fecal microbiota transplantation (FMT) will&#xD;
      be able to prevent additional recurrences of infections due to MDRO by suppressing or&#xD;
      reversing enteric colonization with MDRO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective pilot study of fecal microbiota transplantation in patients with a&#xD;
      history of recurrent MDRO infections. Subjects who meet inclusion/exclusion criteria and&#xD;
      provide written, informed consent will provide a pre-FMT stool sample. The FMT will be&#xD;
      administered by enema in the outpatient setting by trained personnel. Patients will provide&#xD;
      stool samples 30 days, 6 months, and 12 months post-FMT. The subjects will also be monitored&#xD;
      for potential adverse events, recurrence of MDRO infections, infections that may be related&#xD;
      to FMT, and worsening of existing comorbidities or development of new comorbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events)</measure>
    <time_frame>12 months post-FMT</time_frame>
    <description>Incidence and severity of solicited and serious adverse events within 12 months of FMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MDRO Infection Status Post-FMT (Number of Subjects With MDRO Infections)</measure>
    <time_frame>30 days, 6 months, and 12 months post-FMT</time_frame>
    <description>Number of subjects with MDRO infections 30 days, 6 months, and 12 months post-FMT.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Infection With Multi-drug Resistant Organisms</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 150mL of fecal microbiota product via enema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbiota transplantation (FMT)</intervention_name>
    <description>Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <other_name>FMT</other_name>
    <other_name>stool transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria will include:&#xD;
&#xD;
          -  Age â‰¥18 years old.&#xD;
&#xD;
          -  Outpatient status at time of FMT.&#xD;
&#xD;
          -  History of at least three recurrent infections due to an MDRO; at least two recurrent,&#xD;
             severe infections due to MDRO requiring hospitalization; or at least two recurrent&#xD;
             infections due to MDRO for which only antimicrobials with rate limiting toxicities&#xD;
             (see above) are available AND the MDRO is likely of enteric origin. Only MDROs of&#xD;
             likely enteric origin will be included.&#xD;
&#xD;
          -  Be without active infection due to the MDRO at the time of FMT.&#xD;
&#xD;
          -  Not be receiving antimicrobials (therapeutic or suppressive) within 48 hours of FMT.&#xD;
&#xD;
        Exclusion criteria will include:&#xD;
&#xD;
          -  Subjects &lt;18 years old.&#xD;
&#xD;
          -  Subjects unable to be seen as an outpatient.&#xD;
&#xD;
          -  Use of enteral or systemic antimicrobials at time of FMT.&#xD;
&#xD;
          -  Planned use of enteral or systemic antimicrobials up to 6 months post-FMT.&#xD;
&#xD;
          -  Pregnancy or inability/unwillingness to use contraceptives.&#xD;
&#xD;
          -  Recent intra-abdominal surgery&#xD;
&#xD;
          -  Short gut syndrome&#xD;
&#xD;
          -  Gastrointestinal motility disorders&#xD;
&#xD;
          -  Use of medications that affect intestinal motility an inability to cease using those&#xD;
             medications at the time of FMT.&#xD;
&#xD;
          -  Post-allogeneic hematopoietic stem cell transplant recipients with previous or current&#xD;
             gastrointestinal graft versus host disease.&#xD;
&#xD;
          -  ANC &lt;500/mm3&#xD;
&#xD;
          -  HIV+ and not well controlled on antiretroviral therapy, or CD4+ &lt;200/ mm3&#xD;
&#xD;
          -  At increased risk for peritonitis: presence of intra-abdominal devices, receiving&#xD;
             peritoneal dialysis, or ascites.&#xD;
&#xD;
          -  Any acute illness&#xD;
&#xD;
          -  Recurrent C. difficile infection.&#xD;
&#xD;
          -  Unlikely to survive for 3 months.&#xD;
&#xD;
          -  Investigator feels the risks of FMT outweigh potential benefit, including other&#xD;
             conditions or medications that the investigator determines puts the subject at greater&#xD;
             risk from FMT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik R Dubberke, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>colonization</keyword>
  <keyword>antibiotic resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02312986/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fecal Microbiota Transplantation</title>
          <description>Subjects will receive 150mL of fecal microbiota product via enema.&#xD;
Fecal microbiota transplantation (FMT): Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant was enrolled in this trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Fecal Microbiota Transplantation</title>
          <description>Subjects will receive 150mL of fecal microbiota product via enema.&#xD;
Fecal microbiota transplantation (FMT): Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events)</title>
        <description>Incidence and severity of solicited and serious adverse events within 12 months of FMT.</description>
        <time_frame>12 months post-FMT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fecal Microbiota Transplantation</title>
            <description>Subjects will receive 150mL of fecal microbiota product via enema.&#xD;
Fecal microbiota transplantation (FMT): Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events)</title>
          <description>Incidence and severity of solicited and serious adverse events within 12 months of FMT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Solicited adverse events related to FMT</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any serious adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MDRO Infection Status Post-FMT (Number of Subjects With MDRO Infections)</title>
        <description>Number of subjects with MDRO infections 30 days, 6 months, and 12 months post-FMT.</description>
        <time_frame>30 days, 6 months, and 12 months post-FMT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fecal Microbiota Transplantation</title>
            <description>Subjects will receive 150mL of fecal microbiota product via enema.&#xD;
Fecal microbiota transplantation (FMT): Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
          </group>
        </group_list>
        <measure>
          <title>MDRO Infection Status Post-FMT (Number of Subjects With MDRO Infections)</title>
          <description>Number of subjects with MDRO infections 30 days, 6 months, and 12 months post-FMT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MDRO infection at 30 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MDRO infection at 6 months post-FMT</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MDRO infection at 12 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fecal Microbiota Transplantation</title>
          <description>Subjects will receive 150mL of fecal microbiota product via enema.&#xD;
Fecal microbiota transplantation (FMT): Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Reske, MPH, Research Coordinator</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>314-747-4041</phone>
      <email>kreske@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

